Treatment of myasthenia gravis

Australian Prescriber

Volumn 30, Issue 6, 2007, Pages 156-160

  Reddel, Stephen W ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Azathioprine; Immunosuppression; Prednisone; Pyridostigmine; Thymectomy

Indexed keywords

ACETYLCHOLINESTERASE; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EDROPHONIUM; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PYRIDOSTIGMINE; RITUXIMAB;

CLINICAL FEATURE; DISEASE SEVERITY; FASCICULATION; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MORBIDITY; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NEUROMUSCULAR TRANSMISSION; PLASMAPHERESIS; REVIEW; THYMECTOMY; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 36849085804     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2007.093     Document Type: Review

References (2)

1. Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984;15:291-8.
2. Palace J, Newsom-Davis J, Lecky B; Myasthenia Gravis Study Group. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998;50:1778-83.